What is the recommended treatment for an acute gout flare?

Treatment of Acute Gout Flare

Corticosteroids are the preferred first-line treatment for acute gout flares because they provide efficacy equal to NSAIDs while causing fewer adverse effects and costing less. 1

First-Line Anti-Inflammatory Options

Corticosteroids (Preferred First-Line)

• Prednisolone 35 mg orally once daily for 5 days is the recommended regimen. 2, 1
• Corticosteroids demonstrate equivalent pain relief compared to NSAIDs but with superior safety profiles in short-term use. 2
• Contraindications include systemic fungal infections and known hypersensitivity. 1
• Short-term adverse effects include mood disturbances, elevated blood glucose, immunosuppression, and fluid retention. 1
• Despite these potential effects, corticosteroids remain safer than NSAIDs for most patients when used for acute flares. 2

NSAIDs (Alternative First-Line)

• All NSAIDs have equivalent efficacy for acute gout—indomethacin is not superior to naproxen, ibuprofen, or other NSAIDs. 2, 1
• This is important because indomethacin is traditionally considered first-line, but moderate-quality evidence shows no advantage. 2
• Avoid NSAIDs in patients with renal disease, heart failure, or cirrhosis. 2, 1
• Major adverse effects include dyspepsia, gastrointestinal perforation, ulceration, and bleeding. 1
• NSAIDs should also be avoided in patients with cardiovascular disease due to increased risk of adverse cardiovascular events. 3

Colchicine (Alternative First-Line)

• Low-dose colchicine (1.2 mg followed by 0.6 mg one hour later) is the recommended regimen. 1
• This low-dose regimen is as effective as high-dose schedules but causes markedly fewer gastrointestinal adverse effects. 1
• High-dose colchicine regimens (e.g., 1.2 mg followed by 0.6 mg hourly for 6 hours) should be avoided—they provide no additional benefit and cause significantly more toxicity. 1
• Colchicine is the most expensive non-biologic option for acute gout. 2, 1
• Contraindicated in patients with renal or hepatic impairment who are receiving potent CYP3A4 or P-glycoprotein inhibitors. 1
• Common adverse effects include diarrhea (23% with low-dose vs 77% with high-dose), nausea, vomiting, and abdominal cramps. 1
• Colchicine may reduce the risk of myocardial infarction in patients with cardiovascular disease, making it a safer choice in this population. 3

Initiating Urate-Lowering Therapy During an Acute Flare

• Starting urate-lowering therapy (ULT) during an acute gout flare does not prolong the duration or increase the severity of the flare. 1
• This approach improves care efficiency and capitalizes on heightened patient motivation to adhere to therapy. 1
• When ULT is initiated, concomitant anti-inflammatory prophylaxis must be provided. 1
• Acceptable prophylactic agents include colchicine, NSAIDs, or low-dose corticosteroids. 1
• Anti-inflammatory prophylaxis should be continued for 3–6 months rather than shorter durations (<3 months). 1
• High-quality evidence shows that prophylactic therapy with low-dose colchicine or low-dose NSAIDs effectively reduces acute gout flares when initiating ULT, and moderate-quality evidence supports continuing prophylaxis for more than 8 weeks. 2
• Gout flares are common (approximately 30% of patients) in the three months immediately after stopping anti-inflammatory prophylaxis, but rates return to baseline levels seen during prophylaxis thereafter. 4
• Patients should be counseled about this increased flare risk and have a plan for effective gout flare management during the three months after stopping prophylaxis. 4

Common Pitfalls to Avoid

• Do not use high-dose colchicine regimens—they cause significantly more gastrointestinal toxicity without additional therapeutic benefit. 1
• Do not assume indomethacin is superior to other NSAIDs—moderate-quality evidence shows no clinically important differences among NSAID options. 2, 1
• Do not delay initiating ULT in patients with recurrent gout (≥2 episodes per year) or problematic gout (tophi, chronic kidney disease, urolithiasis). 1
• Do not start long-term ULT after a single gout attack or when attacks are infrequent (<2 per year). 1